Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7082951 | 0.93 | ABCB11 (0.43) | ABCB11GAAKDM4ELMNAMAPT | |
| SCHEMBL7086861 | 0.90 | GAA (0.41) | GAAKDM4ELMNAMAPTPTGS2 | |
| SCHEMBL6780153 | 0.89 | ABCB11 (0.54) | ABCB11GAAKDM4ELMNAMAPT | |
| SCHEMBL7089748 | 0.82 | GAA (0.41) | ABCB11GAAKDM4ELMNAMAPT | |
| SCHEMBL7083815 | 0.81 | ABCB11 (0.61) | ABCB11KDM4EMAPTPTGS2CCR2 | |
| SCHEMBL6595452 | 0.80 | ABCB11 (0.56) | ABCB11GAAKDM4ELMNAMAPT | |
| SCHEMBL6782383 | 0.80 | ABCB11 (0.56) | ABCB11GAAKDM4ELMNAMAPT | |
| SCHEMBL7601514 | 0.78 | GAA (0.41) | ABCB11GAAKDM4ELMNAMAPT | |
| SCHEMBL7592778 | 0.76 | ABCB11 (0.61) | ABCB11GAAKDM4ELMNAMAPT | |
| SCHEMBL7084148 | 0.74 | ABCB11 (0.61) | ABCB11KDM4EMAPTPTGS2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144339-A1 | Indole derivatives as mcp-1 receptor antagonists | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144339-A1 | Indole derivatives as mcp-1 receptor antagonists | CCR2, CCR1, CCR5 | ABCB11 391/4885GAA 4790/4885KDM4E 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.